EDRF1 Activators
Items 11 to 19 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is another potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation and potential enhancement of EBPL activity if EBPL is regulated by such phosphatases. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, could possibly inhibit EDRF1 by impacting erythropoiesis through cellular signaling effects. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, could possibly inhibit EDRF1 by altering signaling pathways in erythroid cells. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits NF-κB activation by blocking phosphorylation of IκBα, leading to modulation of proteins regulated by NF-κB, which could include EBPL if it is a target of NF-κB. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK2 inhibitor, could possibly inhibit EDRF1 by modulating JAK-STAT signaling pathways, relevant to erythropoiesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can increase the activity of certain proteins by inhibiting their negative regulation by PI3K. If EBPL is negatively regulated by a PI3K pathway, its activity could be enhanced. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101, a PI3K inhibitor, could possibly inhibit EDRF1 by altering PI3K-Akt signaling pathways involved in cell differentiation. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
ABT-737, a Bcl-xL inhibitor, could possibly inhibit EDRF1 through its role in apoptosis and cell survival processes related to erythropoiesis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 can lead to alterations in the activity of proteins in the p38 MAPK pathway, potentially enhancing EBPL if it is regulated by p38-dependent phosphorylation. | ||||||